The CR-ABL1 Kinase Domain Mutation Analysis (IRMA Test) is a crucial genetic test for blood cancers like CML, identifying specific mutations (like T315I) in the BCR-ABL1 gene that cause resistance to Tyrosine Kinase Inhibitor (TKI) drugs, guiding treatment changes for better outcomes. “IRMA” stands for IMatinib Resistance Mutation Analysis, using methods like Sanger sequencing or Next-Generation Sequencing (NGS) on blood samples to detect these resistance markers, helping doctors choose the right TKI